##{"id":96541,"date":"2021-09-15T17:27:00","date_gmt":"2021-09-15T07:27:00","guid":{"rendered":"https:\/\/www.fnarena.com\/index.php\/2021\/09\/15\/us-patent-and-trademark-office-grants-new-patent-for-dep-cabazitaxel-one-of-starpharmas-phase-2-clinical-stage-cancer-treatments\/"},"modified":"2021-09-15T17:27:00","modified_gmt":"2021-09-15T07:27:00","slug":"us-patent-and-trademark-office-grants-new-patent-for-dep-cabazitaxel-one-of-starpharmas-phase-2-clinical-stage-cancer-treatments","status":"publish","type":"post","link":"https:\/\/staging.fnarena.com\/index.php\/2021\/09\/15\/us-patent-and-trademark-office-grants-new-patent-for-dep-cabazitaxel-one-of-starpharmas-phase-2-clinical-stage-cancer-treatments\/","title":{"rendered":"US Patent and Trademark Office grants new patent for DEP\u00ae cabazitaxel, one of Starpharma’s phase 2 clinical-stage cancer treatments"},"content":{"rendered":"

MELBOURNE, Australia<\/span>, Sept. 15, 2021<\/span> \/PRNewswire\/ — DEP^{®<\/sup> cabazitaxel<\/a> is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana^{®<\/sup>), which had global sales of US$536 million<\/span> in 2020.}}Starpharma<\/a>‘s DEP^{®<\/sup> cabazitaxel is a water soluble, polysorbate-80 free formulation, without requirement for pre-treatment with steroids nor G-CSF to reduce the risk of severe bone marrow toxicity. <\/p>\n}

In preclinical and clinical studies, DEP^{®<\/sup> cabazitaxel has shown an improved side effect profile, notably markedly reduced bone marrow toxicity demonstrated by lower rates of severe neutropenia, thrombocytopenia, and severe anaemia, which are experienced by a significant proportion of Jevtana^{®<\/sup> treated patients. <\/p>\n}}

The composition of matter<\/i> patent builds on Starpharma’s suite of existing international patents for DEP^{®<\/sup> cabazitaxel. It specifically covers a DEP^{®<\/sup> dendrimer conjugated to multiple cabazitaxel drug molecules via a particular releasable linker, with a patent term to 2039 and potential for a 5-year extension. <\/p>\n}}

Starpharma CEO, Dr Jackie Fairley<\/span>, commented: "The grant of this new US patent illustrates the unique and compelling benefits of Starpharma’s DEP^{®<\/sup> drug delivery technology and DEP^{®<\/sup> cabazitaxel. We look forward to completing the phase 2 clinical program for DEP^{®<\/sup> cabazitaxel, in parallel with commercial licensing discussions."<\/p>\n}}}

DEP^{®<\/sup> cabazitaxel<\/a> is in late phase 2 clinical development, recruiting patients with solid tissue tumours, including prostate, ovarian and gastro-oesophageal cancers. <\/p>\n}

Encouraging efficacy signals have been observed in multiple tumour types, including in prostate cancer where radiological responses, significant reductions in prostate-specific antigen (PSA) and no new bone metastases were observed. These efficacy signals were observed despite patients having been heavily pre-treated with an average of 30 prior cycles of treatment, and in some cases with more than 100 cycles and up to 10 different treatment regimens. Patients treated with DEP^{®<\/sup> cabazitaxel have also exhibited encouraging efficacy signals in gastro-oesophageal, ovarian, cholangiocarcinoma, lung and head and neck cancers.<\/p>\n}

DEP^{®<\/sup> cabazitaxel was developed using Starpharma’s proprietary DEP^{®<\/sup> drug delivery platform, used by the company and partners to create novel nanoparticle formulations of existing and new drugs to enhance their therapeutic and commercial value. DEP^{®<\/sup> drug delivery is applicable to a wide range of drugs in oncology and other therapeutic areas. Starpharma has three phase 2 clinical-stage DEP^{®<\/sup> assets, multiple preclinical DEP^{®<\/sup> programs, and several DEP^{®<\/sup> commercial partnerships with companies, including AstraZeneca, Chase Sun<\/span> and Merck & Co., Inc., to develop DEP^{®<\/sup> versions of their products or ADCs. <\/p>\n}}}}}}}

investor.relations@starpharma.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"